We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: GLP-1 RA use tied to decrease charge of venous thromboembolism in diabetes
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Health > GLP-1 RA use tied to decrease charge of venous thromboembolism in diabetes
GLP-1 RA use tied to decrease charge of venous thromboembolism in diabetes
Health

GLP-1 RA use tied to decrease charge of venous thromboembolism in diabetes

Last updated: November 14, 2024 10:37 pm
Editorial Board Published November 14, 2024
Share
SHARE

For sufferers with kind 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is related to a decrease danger for venous thromboembolism (VTE), in accordance with a research scheduled for presentation on the annual assembly of the American Society of Hematology, to be held from Dec. 7 to 10 in San Diego.

Cho Han Chiang, M.D., from Mount Auburn Hospital in Cambridge, Massachusetts, and colleagues examined whether or not GLP-1 RA use would cut back the danger for VTE amongst sufferers with T2DM in a retrospective, propensity score-matched multicenter database evaluation. Sufferers who obtained GLP-1 RAs had been in comparison with those that obtained dipeptidyl peptidase-4 (DPP-4) inhibitors; after propensity rating matching, the ultimate evaluation included two cohorts of 168,428 sufferers every.

The researchers discovered that the incidence of VTE was 11.0 versus 12.9 occasions per 1,000 patient-years within the GLP-1 RA and DPP-4 inhibitor cohorts, respectively, with an 18% decrease danger for VTE for these receiving GLP-1 RAs (hazard ratio [HR], 0.82). In contrast with these on DPP-4 inhibitors, sufferers receiving GLP-1 RAs had a decrease danger for pulmonary embolism and deep venous thrombosis (HRs, 0.78 and 0.85, respectively). In a subgroup evaluation, the variations in VTE charges had been related for sufferers with and with out weight problems (HRs, 0.80 and 0.82, respectively).

“These results support the hypothesis that use of GLP-1 RA can lead to a reduction in VTE risk,” the authors write. “Further studies are needed to elucidate the mechanisms and causality underlying the association between GLP-1 RA use and reduction of VTE risk, and whether these findings extend to patients using GLP-1 RA for weight control without T2DM.”

Extra info:
AbstractMore Info

2024 HealthDay. All rights reserved.

Quotation:
GLP-1 RA use tied to decrease charge of venous thromboembolism in diabetes (2024, November 14)
retrieved 14 November 2024
from https://medicalxpress.com/information/2024-11-glp-ra-venous-thromboembolism-diabetes.html

This doc is topic to copyright. Other than any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.

You Might Also Like

Throughout being pregnant, newer antiseizure drugs could also be safer than older medication

Examine suggests some maternal HIV infections could also be missed throughout being pregnant

The significance of psychological resilience in ageing and widowhood

Music remedy could ease misery for dementia sufferers in hospital wards

Eye scan can reveal danger of getting a coronary heart assault or stroke

TAGGED:DiabetesGLP1ratethromboembolismtiedvenous
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
Research illuminates the structural options of reminiscence formation at mobile and subcellular ranges
Health

Research illuminates the structural options of reminiscence formation at mobile and subcellular ranges

Editorial Board March 21, 2025
Is DeepSeek actually sending knowledge to China? Let’s decode
FCC launches effort to ‘root out’ DEI packages, starting with Comcast
Not a Morning Individual? 15 Energizing Exercises That’ll Persuade You In any other case
Get a Soar Begin on Your Resolutions With These Wholesome New 12 months’s Eve Recipes

You Might Also Like

Eight infants born after mitochondrial donation therapy to scale back transmission of mitochondrial DNA illness
Health

Eight infants born after mitochondrial donation therapy to scale back transmission of mitochondrial DNA illness

July 16, 2025
WHO, UNICEF say greater than 14 million infants worldwide stay unvaccinated
Health

WHO, UNICEF say greater than 14 million infants worldwide stay unvaccinated

July 16, 2025
Common train might assist forestall fatty liver illness by means of bile acid metabolism
Health

Common train might assist forestall fatty liver illness by means of bile acid metabolism

July 16, 2025
From tea towels to TV remotes: Eight on a regular basis bacterial hotspots, and the best way to clear them
Health

From tea towels to TV remotes: Eight on a regular basis bacterial hotspots, and the best way to clear them

July 16, 2025

Categories

  • Health
  • Sports
  • Politics
  • Entertainment
  • Technology
  • World
  • Art

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?